The DOI matches its Crossref record; 236 of the 236 references it cites were found in a registry or an index.
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Open accessAbstract
Background: Breast cancer is associated with a relatively good prognosis. Prognostic factors examined to date are related to early recurrence while those related to late recurrence and their countermeasures remain unclear. Therefore, we examined the factors related to late recurrence. Patients and Methods: From January 1980 to August 2012, 4,774 patients who underwent primary treatment and estrogen (ER) and progesterone receptor (PgR) assessment were enrolled in this study. The patients were divided into two groups, those with a follow-up period <10 years and those without any recurrence at 10 years but who continued follow-up examinations. Recurrence occurred in 711 patients followed up for <10 years and in 51 patients for ≥10 years. Results: The overall 10-year cumulative disease-free survival rate was 79.5%, and the recurrence rate at ≥10 years was 5.8%. A multivariate analysis revealed that the factors related to late recurrence were PgR positivity and positive nodes. This result differed from that for early recurrence in terms of ER/PgR, Ki-67 index and p53 overexpression. Conclusion: PgR positivity and lymph node metastases significantly correlated with late recurrence. Therefore, it is important to evaluate appropriate measures such as treatment period and treatment regimen for hormone-sensitive patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Research works printed but not linked: 3
- 10.1007/s10147-006-0601-6 · doi:10.1007/s10147-006-0601-6
- 10.1186/1477-7819-9-131 · doi:10.1186/1477-7819-9-131
- 10.1186/bcr2143 · doi:10.1186/bcr2143
Cited by
Items 401–500 of 787
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
Tischkowitz, M., Brunet, J.-S., Bégin, L. R., Huntsman, D. G., Cheang, M. C., Akslen, L. A., Nielsen, T. O., & Foulkes, W. D. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-134 · Cited by 365
Jiang, Y., Chen, L., Zhang, H., & Xiao, X. (2019) · PLOS ONE · doi:10.1371/journal.pone.0214587 · Cited by 365
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
Dienstmann, R., Rodon, J., Prat, A., Perez-Garcia, J., Adamo, B., Felip, E., Cortes, J., Iafrate, A. J., Nuciforo, P., & Tabernero, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt419 · Cited by 365
Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies
Nounou, M. I., ElAmrawy, F., Ahmed, N., Abdelraouf, K., Goda, S., & Syed-Sha-Qhattal, H. (2015) · Breast Cancer: Basic and Clinical Research · doi:10.4137/bcbcr.s29420 · Cited by 364
Li, H., Zhu, Y., Burnside, E. S., Huang, E., Drukker, K., Hoadley, K. A., Fan, C., Conzen, S. D., Zuley, M., Net, J. M., et al. (2016) · npj Breast Cancer · doi:10.1038/npjbcancer.2016.12 · Cited by 364
Towards targeting the breast cancer immune microenvironment
Harris, M. A., Savas, P., Virassamy, B., O’Malley, M. M. R., Kay, J., Mueller, S. N., Mackay, L. K., Salgado, R., & Loi, S. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00714-6 · Cited by 363
The I-SPY 1 TRIAL Investigators, Esserman, L. J., Berry, D. A., Cheang, M. C. U., Yau, C., Perou, C. M., Carey, L., DeMichele, A., Gray, J. W., Conway-Dorsey, K., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1895-2 · Cited by 362
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
Pandey, K., An, H., Kim, S. K., Lee, S. A., Kim, S., Lim, S. M., Kim, G. M., Sohn, J., & Moon, Y. W. (2019) · International Journal of Cancer · doi:10.1002/ijc.32020 · Cited by 361
Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types
Iglesia, M. D., Parker, J. S., Hoadley, K. A., Serody, J. S., Perou, C. M., & Vincent, B. G. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw144 · Cited by 360
Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness
Jessani, N., Liu, Y., Humphrey, M., & Cravatt, B. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162187599 · Cited by 359
Loi, S., Haibe-Kains, B., Majjaj, S., Lallemand, F., Durbecq, V., Larsimont, D., Gonzalez-Angulo, A. M., Pusztai, L., Symmans, W. F., Bardelli, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907011107 · Cited by 356
Pan, J. J., Ng, W. T., Zong, J. F., Chan, L. L. K., O'Sullivan, B., Lin, S. J., Sze, H. C. K., Chen, Y. B., Choi, H. C. W., Guo, Q. J., et al. (2016) · Cancer · doi:10.1002/cncr.29795 · Cited by 356
The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis
Pedersen, R. N., Esen, B. Ö., Mellemkjær, L., Christiansen, P., Ejlertsen, B., Lash, T. L., Nørgaard, M., & Cronin-Fenton, D. (2022) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab202 · Cited by 356
Technologies for circulating tumor cell separation from whole blood
Bankó, P., Lee, S. Y., Nagygyörgy, V., Zrínyi, M., Chae, C. H., Cho, D. H., & Telekes, A. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0735-4 · Cited by 358
Saal, L. H., Gruvberger-Saal, S. K., Persson, C., Lövgren, K., Jumppanen, M., Staaf, J., Jönsson, G., Pires, M. M., Maurer, M., Holm, K., et al. (2008) · Nature Genetics · doi:10.1038/ng.2007.39 · Cited by 355
Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study
Wu, Q., Li, J., Zhu, S., Wu, J., Chen, C., Liu, Q., Wei, W., Zhang, Y., & Sun, S. (2017) · Oncotarget · doi:10.18632/oncotarget.15856 · Cited by 355
Distinct functions of AKT isoforms in breast cancer: a comprehensive review
Hinz, N., & Jücker, M. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0450-3 · Cited by 355
Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis
Zhang, L., Awadalla, M., Mahmood, S. S., Nohria, A., Hassan, M. Z. O., Thuny, F., Zlotoff, D. A., Murphy, S. P., Stone, J. R., Golden, D. L. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa051 · Cited by 355
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity
Van Keymeulen, A., Lee, M. Y., Ousset, M., Brohée, S., Rorive, S., Giraddi, R. R., Wuidart, A., Bouvencourt, G., Dubois, C., Salmon, I., et al. (2015) · Nature · doi:10.1038/nature14665 · Cited by 354
Pappa, K. I., Polyzos, A., Jacob-Hirsch, J., Amariglio, N., Vlachos, G. D., Loutradis, D., & Anagnou, N. P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0142229 · Cited by 354
Delta-radiomics features for the prediction of patient outcomes in non–small cell lung cancer
Fave, X., Zhang, L., Yang, J., Mackin, D., Balter, P., Gomez, D., Followill, D., Jones, A. K., Stingo, F., Liao, Z., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00665-z · Cited by 353
Cell-Cycle Therapeutics Come of Age
Ingham, M., & Schwartz, G. K. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.0032 · Cited by 353
Li, Y., Zou, L., Li, Q., Haibe-Kains, B., Tian, R., Li, Y., Desmedt, C., Sotiriou, C., Szallasi, Z., Iglehart, J. D., et al. (2010) · Nature Medicine · doi:10.1038/nm.2090 · Cited by 352
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Lee, J.-M., Ledermann, J. A., & Kohn, E. C. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt384 · Cited by 352
Detecting Circulating Tumor Cells: Current Challenges and New Trends
Hong, B., & Zu, Y. (2013) · Theranostics · doi:10.7150/thno.5195 · Cited by 351
Bao, Y., Wang, L., Shi, L., Yun, F., Liu, X., Chen, Y., Chen, C., Ren, Y., & Jia, Y. (2019) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-019-0162-0 · Cited by 351
(2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.08.031 · Cited by 351
Paradoxical Relationship between Chromosomal Instability and Survival Outcome in Cancer
Birkbak, N. J., Eklund, A. C., Li, Q., McClelland, S. E., Endesfelder, D., Tan, P., Tan, I. B., Richardson, A. L., Szallasi, Z., & Swanton, C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3667 · Cited by 350
Human breast cancer metastases to the brain display GABAergic properties in the neural niche
Neman, J., Termini, J., Wilczynski, S., Vaidehi, N., Choy, C., Kowolik, C. M., Li, H., Hambrecht, A. C., Roberts, E., & Jandial, R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322098111 · Cited by 349
Radiation induced secondary malignancies: a review article
Dracham, C. B., Shankar, A., & Madan, R. (2018) · Radiation Oncology Journal · doi:10.3857/roj.2018.00290 · Cited by 349
Provencio, M., Serna-Blasco, R., Nadal, E., Insa, A., García-Campelo, M. R., Casal Rubio, J., Dómine, M., Majem, M., Rodríguez-Abreu, D., Martínez-Martí, A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02660 · Cited by 349
LSimpute: accurate estimation of missing values in microarray data with least squares methods
Bo, T. H. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh026 · Cited by 348
MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing
Farazi, T. A., Horlings, H. M., ten Hoeve, J. J., Mihailovic, A., Halfwerk, H., Morozov, P., Brown, M., Hafner, M., Reyal, F., van Kouwenhove, M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0608 · Cited by 346
Manahan, E. R., Kuerer, H. M., Sebastian, M., Hughes, K. S., Boughey, J. C., Euhus, D. M., Boolbol, S. K., & Taylor, W. A. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07549-8 · Cited by 346
Abdulkarim, B. S., Cuartero, J., Hanson, J., Deschênes, J., Lesniak, D., & Sabri, S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4714 · Cited by 345
Dadhania, V., Zhang, M., Zhang, L., Bondaruk, J., Majewski, T., Siefker-Radtke, A., Guo, C. C., Dinney, C., Cogdell, D. E., Zhang, S., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.08.036 · Cited by 345
Widespread intron retention diversifies most cancer transcriptomes
Dvinge, H., & Bradley, R. K. (2015) · Genome Medicine · doi:10.1186/s13073-015-0168-9 · Cited by 344
Functional Enhancers Shape Extrachromosomal Oncogene Amplifications
Morton, A. R., Dogan-Artun, N., Faber, Z. J., MacLeod, G., Bartels, C. F., Piazza, M. S., Allan, K. C., Mack, S. C., Wang, X., Gimple, R. C., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.039 · Cited by 343
Fully Automatic Quantification of Microarray Image Data
Jain, A. N., Tokuyasu, T. A., Snijders, A. M., Segraves, R., Albertson, D. G., & Pinkel, D. (2002) · Genome Research · doi:10.1101/gr.210902 · Cited by 342
Gene expression analyses reveal molecular relationships among 20 regions of the human CNS
Roth, R. B., Hevezi, P., Lee, J., Willhite, D., Lechner, S. M., Foster, A. C., & Zlotnik, A. (2006) · Neurogenetics · doi:10.1007/s10048-006-0032-6 · Cited by 342
Lehmann, B. D., Bauer, J. A., Schafer, J. M., Pendleton, C. S., Tang, L., Johnson, K. C., Chen, X., Balko, J. M., Gómez, H., Arteaga, C. L., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0406-x · Cited by 342
Viale, G., Giobbie-Hurder, A., Regan, M. M., Coates, A. S., Mastropasqua, M. G., Dell'Orto, P., Maiorano, E., MacGrogan, G., Braye, S. G., Öhlschlegel, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.0829 · Cited by 340
Intron retention is a widespread mechanism of tumor-suppressor inactivation
Jung, H., Lee, D., Lee, J., Park, D., Kim, Y. J., Park, W.-Y., Hong, D., Park, P. J., & Lee, E. (2015) · Nature Genetics · doi:10.1038/ng.3414 · Cited by 339
A clinically relevant gene signature in triple negative and basal-like breast cancer
Rody, A., Karn, T., Liedtke, C., Pusztai, L., Ruckhaeberle, E., Hanker, L., Gaetje, R., Solbach, C., Ahr, A., Metzler, D., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr3035 · Cited by 338
Increased global transcription activity as a mechanism of replication stress in cancer
Kotsantis, P., Silva, L. M., Irmscher, S., Jones, R. M., Folkes, L., Gromak, N., & Petermann, E. (2016) · Nature Communications · doi:10.1038/ncomms13087 · Cited by 336
Goetz, M. P., Sangkuhl, K., Guchelaar, H., Schwab, M., Province, M., Whirl‐Carrillo, M., Symmans, W. F., McLeod, H. L., Ratain, M. J., Zembutsu, H., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1007 · Cited by 336
Cimino-Mathews, A., Thompson, E., Taube, J. M., Ye, X., Lu, Y., Meeker, A., Xu, H., Sharma, R., Lecksell, K., Cornish, T. C., et al. (2016) · Human Pathology · doi:10.1016/j.humpath.2015.09.003 · Cited by 336
Within the fold: assessing differential expression measures and reproducibility in microarray assays
Yang, I. V., Chen, E., Hasseman, J. P., Liang, W., Frank, B. C., Wang, S., Sharov, V., Saeed, A. I., White, J., Li, J., et al. (2002) · Genome Biology · doi:10.1186/gb-2002-3-11-research0062 · Cited by 336
Kattan, M. W., Hess, K. R., Amin, M. B., Lu, Y., Moons, K. G. M., Gershenwald, J. E., Gimotty, P. A., Guinney, J. H., Halabi, S., Lazar, A. J., et al. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21339 · Cited by 336
Weigelt, B., Ghajar, C. M., & Bissell, M. J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.01.001 · Cited by 335
Moncada-Torres, A., van Maaren, M. C., Hendriks, M. P., Siesling, S., & Geleijnse, G. (2021) · Scientific Reports · doi:10.1038/s41598-021-86327-7 · Cited by 335
Subtyping of triple‐negative breast cancer: Implications for therapy
Abramson, V. G., Lehmann, B. D., Ballinger, T. J., & Pietenpol, J. A. (2015) · Cancer · doi:10.1002/cncr.28914 · Cited by 333
Breast cancer intra-tumor heterogeneity
Martelotto, L. G., Ng, C. K., Piscuoglio, S., Weigelt, B., & Reis-Filho, J. S. (2014) · Breast Cancer Research · doi:10.1186/bcr3658 · Cited by 332
The neutrophil-to-lymphocyte ratio: a narrative review
Socorro Faria, S., Fernandes Jr, P. C., Barbosa Silva, M. J., Lima, V. C., Fontes, W., Freitas-Junior, R., Eterovic, A. K., & Forget, P. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.702 · Cited by 332
Rondinelli, B., Gogola, E., Yücel, H., Duarte, A. A., van de Ven, M., van der Sluijs, R., Konstantinopoulos, P. A., Jonkers, J., Ceccaldi, R., Rottenberg, S., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3626 · Cited by 332
Mosley, J. D., Gupta, D. K., Tan, J., Yao, J., Wells, Q. S., Shaffer, C. M., Kundu, S., Robinson-Cohen, C., Psaty, B. M., Rich, S. S., et al. (2020) · JAMA · doi:10.1001/jama.2019.21782 · Cited by 332
Zhang, Y., He, Q., Hu, Z., Feng, Y., Fan, L., Tang, Z., Yuan, J., Shan, W., Li, C., Hu, X., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3211 · Cited by 331
Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer
Carrot-Zhang, J., Chambwe, N., Damrauer, J. S., Knijnenburg, T. A., Robertson, A. G., Yau, C., Zhou, W., Berger, A. C., Huang, K.-L., Newberg, J. Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.012 · Cited by 331
Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 331
Recent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 331
The impact of site-specific digital histology signatures on deep learning model accuracy and bias
Howard, F. M., Dolezal, J., Kochanny, S., Schulte, J., Chen, H., Heij, L., Huo, D., Nanda, R., Olopade, O. I., Kather, J. N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24698-1 · Cited by 330
Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring
McGuire, A., Brown, J. A. L., & Kerin, M. J. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9551-7 · Cited by 329
Pathogenesis, prevention, diagnosis and treatment of breast cancer
Shah, R. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.283 · Cited by 329
Proteomic maps of breast cancer subtypes
Tyanova, S., Albrechtsen, R., Kronqvist, P., Cox, J., Mann, M., & Geiger, T. (2016) · Nature Communications · doi:10.1038/ncomms10259 · Cited by 328
Principles and methods for transferring polygenic risk scores across global populations
Kachuri, L., Chatterjee, N., Hirbo, J., Schaid, D. J., Martin, I., Kullo, I. J., Kenny, E. E., Pasaniuc, B., Polygenic Risk Methods in Diverse Populations (PRIMED) Consortium Methods Working Group, Auer, P. L., et al. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-023-00637-2 · Cited by 328
PIK3CAH1047R induces multipotency and multi-lineage mammary tumours
Koren, S., Reavie, L., Couto, J. P., De Silva, D., Stadler, M. B., Roloff, T., Britschgi, A., Eichlisberger, T., Kohler, H., Aina, O., et al. (2015) · Nature · doi:10.1038/nature14669 · Cited by 327
Gene Expression Patterns in Ovarian Carcinomas
Schaner, M. E., Ross, D. T., Ciaravino, G., Sørlie, T., Troyanskaya, O., Diehn, M., Wang, Y. C., Duran, G. E., Sikic, T. L., Caldeira, S., et al. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-05-0279 · Cited by 327
Kuchenbaecker, K. B., McGuffog, L., Barrowdale, D., Lee, A., Soucy, P., Dennis, J., Domchek, S. M., Robson, M., Spurdle, A. B., Ramus, S. J., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw302 · Cited by 327
Breast cancer heterogeneity and its implication in personalized precision therapy
Guo, L., Kong, D., Liu, J., Zhan, L., Luo, L., Zheng, W., Zheng, Q., Chen, C., & Sun, S. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-022-00363-1 · Cited by 327
Madurai Elavarasan, R., & Pugazhendhi, R. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2020.138858 · Cited by 326
SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models
Fedele, C., Ran, H., Diskin, B., Wei, W., Jen, J., Geer, M. J., Araki, K., Ozerdem, U., Simeone, D. M., Miller, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0444 · Cited by 315
A multivariate approach to the integration of multi-omics datasets
Meng, C., Kuster, B., Culhane, A. C., & Gholami, A. M. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-162 · Cited by 324
Jézéquel, P., Loussouarn, D., Guérin-Charbonnel, C., Campion, L., Vanier, A., Gouraud, W., Lasla, H., Guette, C., Valo, I., Verrièle, V., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0550-y · Cited by 321
Metastasis prevention by targeting the dormant niche
Ghajar, C. M. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3910 · Cited by 320
Hereditary breast cancer: new genetic developments, new therapeutic avenues
Campeau, P. M., Foulkes, W. D., & Tischkowitz, M. D. (2008) · Human Genetics · doi:10.1007/s00439-008-0529-1 · Cited by 320
Novel patterns of genome rearrangement and their association with survival in breast cancer
Hicks, J., Krasnitz, A., Lakshmi, B., Navin, N. E., Riggs, M., Leibu, E., Esposito, D., Alexander, J., Troge, J., Grubor, V., et al. (2006) · Genome Research · doi:10.1101/gr.5460106 · Cited by 319
Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
Nissan, M. H., Pratilas, C. A., Jones, A. M., Ramirez, R., Won, H., Liu, C., Tiwari, S., Kong, L., Hanrahan, A. J., Yao, Z., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2625 · Cited by 319
Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence
Kim, R. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1389-7 · Cited by 318
Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland
Shehata, M., Teschendorff, A., Sharp, G., Novcic, N., Russell, I. A., Avril, S., Prater, M., Eirew, P., Caldas, C., Watson, C. J., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3334 · Cited by 306
Dawson, S.-J., Makretsov, N., Blows, F. M., Driver, K. E., Provenzano, E., Le Quesne, J., Baglietto, L., Severi, G., Giles, G. G., McLean, C. A., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605736 · Cited by 317
Eliyatkin, N., Yalcin, E., Zengel, B., Aktaş, S., & Vardar, E. (2015) · Journal of Breast Health · doi:10.5152/tjbh.2015.1669 · Cited by 317
Ki-67 as a prognostic marker according to breast cancer molecular subtype
Nahed, A. S., & Shaimaa, M. Y. (2016) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2016.0066 · Cited by 317
Marra, A., Trapani, D., Viale, G., Criscitiello, C., & Curigliano, G. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00197-2 · Cited by 317
Precision medicine for metastatic breast cancer—limitations and solutions
Arnedos, M., Vicier, C., Loi, S., Lefebvre, C., Michiels, S., Bonnefoi, H., & Andre, F. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.123 · Cited by 317
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
Bibby, A. C., Tsim, S., Kanellakis, N., Ball, H., Talbot, D. C., Blyth, K. G., Maskell, N. A., & Psallidas, I. (2016) · European Respiratory Review · doi:10.1183/16000617.0063-2016 · Cited by 316
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 316
Variation in Gene Expression Patterns in Human Gastric Cancers
Chen, X., Leung, S. Y., Yuen, S. T., Chu, K.-M., Ji, J., Li, R., Chan, A. S. Y., Law, S., Troyanskaya, O. G., Wong, J., et al. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-12-0833 · Cited by 316
Precision Medicine: Disease Subtyping and Tailored Treatment
Wang, R. C., & Wang, Z. (2023) · Cancers · doi:10.3390/cancers15153837 · Cited by 315
van der Pouw Kraan, T. C. T. M., Wijbrandts, C. A., van Baarsen, L. G. M., Voskuyl, A. E., Rustenburg, F., Baggen, J. M., Ibrahim, S. M., Fero, M., Dijkmans, B. A. C., Tak, P. P., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.063412 · Cited by 313
Virtaneva, K., Wright, F. A., Tanner, S. M., Yuan, B., Lemon, W. J., Caligiuri, M. A., Bloomfield, C. D., de la Chapelle, A., & Krahe, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1124 · Cited by 311
Molecular Classification of Gastric Cancer: A New Paradigm
Shah, M. A., Khanin, R., Tang, L., Janjigian, Y. Y., Klimstra, D. S., Gerdes, H., & Kelsen, D. P. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2203 · Cited by 311
Targeted Therapies for Triple-Negative Breast Cancer
Lyons, T. G. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0682-x · Cited by 311
Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns
Holm, K., Hegardt, C., Staaf, J., Vallon-Christersson, J., Jönsson, G., Olsson, H., Borg, Å., & Ringnér, M. (2010) · Breast Cancer Research · doi:10.1186/bcr2590 · Cited by 309
RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers
Nolan, E., Vaillant, F., Branstetter, D., Pal, B., Giner, G., Whitehead, L., Lok, S. W., Mann, G. B., Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Rohrbach, K., et al. (2016) · Nature Medicine · doi:10.1038/nm.4118 · Cited by 309
Angus, L., Smid, M., Wilting, S. M., van Riet, J., Van Hoeck, A., Nguyen, L., Nik-Zainal, S., Steenbruggen, T. G., Tjan-Heijnen, V. C. G., Labots, M., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0507-7 · Cited by 309
Zhao, S. G., Chang, S. L., Erho, N., Yu, M., Lehrer, J., Alshalalfa, M., Speers, C., Cooperberg, M. R., Kim, W., Ryan, C. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0751 · Cited by 308
Recurrent and functional regulatory mutations in breast cancer
Rheinbay, E., Parasuraman, P., Grimsby, J., Tiao, G., Engreitz, J. M., Kim, J., Lawrence, M. S., Taylor-Weiner, A., Rodriguez-Cuevas, S., Rosenberg, M., et al. (2017) · Nature · doi:10.1038/nature22992 · Cited by 307
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality
Kerr, A. J., Dodwell, D., McGale, P., Holt, F., Duane, F., Mannu, G., Darby, S. C., & Taylor, C. W. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102375 · Cited by 307
IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment
Manore, S. G., Doheny, D. L., Wong, G. L., & Lo, H.-W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.866014 · Cited by 307
Lock, E. F., & Dunson, D. B. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt425 · Cited by 306
Metadata
- Authors
- Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N.
- Venue
- Oncology
- Publisher
- S. Karger AG
- Published
- 2013
- Volume
- 85
- Issue
- 2
- Pages
- 100-110
- ISSN
- 0030-2414 (ISSN-L)
- 1423-0232
- OpenAlex
- W2044702943
- Cited by
- 13,166
- References
- 236
- FWCI
- 323.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- creativecommons.org/licenses/by-nc/3.0/ (vor)
- creativecommons.org/licenses/by-nc/3.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.